Literature DB >> 33405052

SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).

A de Juan Ferré1, R Álvarez Álvarez2, A Casado Herráez3, J Cruz Jurado4, A Estival González5, J Martín-Broto6, V Martínez Marín7, A Moreno Vega8, A Sebio García9, C Valverde Morales10.   

Abstract

Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.

Entities:  

Keywords:  Guidelines; Sarcoma; Soft-tissue tumors; Uncommon tumors

Year:  2021        PMID: 33405052     DOI: 10.1007/s12094-020-02534-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  4 in total

1.  Primary intracranial extraskeletal myxoid chondrosarcoma: A case report and review of literature.

Authors:  Zi-You Zhu; Yu-Bo Wang; Han-Yi Li; Xin-Min Wu
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

2.  Sarcomas of the Larynx: One Institution's Experience and Treatment Protocol Analyses.

Authors:  Jaromir Astl; Richard Holy; Inna Tuckova; Tomas Belsan; Miloslav Pala; Jan Rotnagl
Journal:  Medicina (Kaunas)       Date:  2021-02-25       Impact factor: 2.430

3.  Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features.

Authors:  Lei Miao; Shu-Tao Ma; Xu Jiang; Huan-Huan Zhang; Yan-Mei Wang; Meng Li
Journal:  BMC Med Imaging       Date:  2022-07-26       Impact factor: 2.795

4.  Integrated Analysis of the Transcriptome Profile Reveals the Potential Roles Played by Long Noncoding RNAs in Immunotherapy for Sarcoma.

Authors:  Boran Pang; Yongqiang Hao
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.